SYNTEX NAPROSYN/ANAPROX SALES JUMP 19% TO $205.2 MIL. IN FOURTH QUARTER
Executive Summary
Combined worldwide sales of Syntex' Naprosyn (naproxen) and Anaprox (naproxen sodium) jumped 19.4% to $205.2 mil. in the fourth quarter (ended July 31). Sales from the two NSAIDs were up 8% for the fiscal year at $802.5 mil. In the last three months, U.S. sales of Naprosyn and Anaprox jumped 22.1% to $148.4 mil. Naprosyn's share of new prescriptions hit 18.2% in the quarter, a turnaround from a low of 16% in March 1989. Non-U.S. fourth quarter sales rose 12.9%. to $56.8 mil. New products generated approximately $40 mil. in sales and accounted for 45% of the increase in human pharmaceutical sales in the fourth quarter, Syntex said. For the year, revenues from Toradol, Synarel, Cytovene and Cardene totaled approximately $105 mil. Syntex worldwide human pharmaceutical sales climbed 26.6% to $336.5 mil. for the quarter and 13.1% at $1.271 bil. for the year. Corporate revenues rose 13% for the year to $1.5 bil. Net income jumped 49% in the quarter to $75.1 mil., and was 12.6% higher for the year at $341.5 mil.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth